Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain : a multicenter observational study by Bonfill, Xavier et al.
Bonfill et al. BMC Res Notes  (2017) 10:708 
https://doi.org/10.1186/s13104-017-3024-8
RESEARCH NOTE
Clinical interval and diagnostic 
characteristics in a cohort of bladder cancer 
patients in Spain: a multicenter observational 
study
Xavier Bonfill1,2,3, María José Martinez‑Zapata1,2* , Robin W. M. Vernooij2, María José Sánchez1,4, 
María Morales Suárez‑Varela1,5, Javier De la Cruz1,6, José Ignacio Emparanza1,7, Montserrat Ferrer1,8, 
José Ignacio Pijoan1,9, Joan Palou10,11, Stefanie Schmidt8, Eva Madrid12,13,14, Víctor Abraira1, Javier Zamora1,15,16 
and on behalf of the EMPARO‑CU study group
Abstract 
Objective: We performed a cohort study in seven hospitals in Spain to determine the clinical characteristics of 
incident patients with bladder cancer, the diagnostic process, and the conditions that might affect health care interval 
times.
Results: 314 patients with bladder cancer were included, 70.3 (Standard Deviation [SD] 11.2) years old and 85.0% 
male. Clinical stage was T1 in 45.9% of patients. The median interval time between first consultation and diagnosis 
was of 104.0 days (Inter quartile range [IQR]:112.0; range from 0 to 986), being shorter for those patients who attended 
a hospital for their first consultation. The median interval time between diagnosis and first treatment was of 0.0 days 
(IQR: 0.0; range from 0 to 366), being longer when the patient had a pathologic tumor stage ≥ T2a.
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Introduction
Bladder cancer is the ninth most common diagnosed 
cancer worldwide, contributing with 429,793 new cases 
yearly [1]. In Spain it is the fifth most common diagnosed 
cancer with 13,789 new cases yearly [1, 2]. In 2012, the 
estimated number of deaths due to bladder cancer was 
of 165,068 worldwide and 5007 in Spain, making it the 
twelfth leading cause worldwide and the sixth in Spain 
[1].
Bladder cancer is one of the malignant tumors where a 
large proportion of health resources are being allocated 
due to its increasing survival rates and lifelong routine 
monitoring which involves associated treatment costs, 
and high recurrence rates [3–6].
Some international initiatives have been undertaken 
to obtain trustworthy information regarding the health-
care process for bladder cancer patients [7, 8]. In Spain, 
several studies reported information from hospital mini-
mum data sets and hospital-based cancer registries [9, 
10]. These sources of information, however, are quite 
limited in describing the diagnostic processes, therapeu-
tic approaches, and prognostic factors in bladder cancer. 
One study conducted in Spain, estimated the annual inci-
dence of bladder cancer and described the clinical pro-
file of patients with bladder cancer, but did not assess the 
diagnostic and therapeutic processes and potential fac-
tors influencing time intervals [2]. For these reasons, the 
objective of the present study was to examine the clini-
cal care process and health outcomes in incident cases 
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of bladder cancer. In a future article, we will report the 
results related to the clinical follow-up.
Main text
Methods
We performed a multicenter, cohort study of bladder and 
prostate cancer, in Spain [11]. The research ethics com-
mittee from each of the seven tertiary participating hos-
pitals (Additional file  1) approved the protocol. Patient 
recruitment was done from October 2010 to September 
2011. Consecutive patients were selected from the urol-
ogy and oncology departments and the inclusion criteria 
were: (1) being diagnosed of bladder cancer during the 
study period; (2) being diagnosed and treated at one of 
the participating hospitals; and (3) agree to participate 
and sign the informed consent form.
Clinical information was gathered by reviewing the 
medical records and structured interviews to patients 
(Additional file 2). The outcomes of interest were: socio-
demographic data, body mass index (BMI), Charlson 
index, ECOG WHO score, setting of the first consultation, 
tests performed to diagnose bladder cancer, pathological 
results of bladder biopsy, patient tumor clinical stages, 
and time length of diagnostic and therapeutic intervals 
(Fig. 1). The time length from first symptoms to first con-
sultation was defined as the period between the date of 
appearance of the first symptom related to bladder cancer 
and the date of attendance to the first medical visit (coded 
as less than 1  month, between 1 and 12  months, after 
12 months), which then led to a bladder cancer diagnosis. 
For asymptomatic patients, the first consultation date was 
determined by the date when the bladder biopsy was per-
formed. We took the positive biopsy report as the con-
firmatory diagnosis of the disease, whose date was used to 
calculate the diagnostic interval. The therapeutic interval 
was defined as the period between the dates of the patho-
logical diagnosis and the initiation of the first treatment. 
For categorical variables we calculated relative frequen-
cies; and for continuous variables, the mean and standard 
deviation (SD) or median and interquartile range (IQR) if 
skewed variables.
We assessed the association between time variables and 
potential predictors by using multilevel logistic regres-
sion models (patients at first level and hospitals at second 
level). As potential predictors we considered the follow-
ing variables: age, BMI, gender, educational level, ECOG 
WHO score, setting of the first consultation, primary 
tumor clinical stage, and time since appearance of first 
symptoms. Continuous time variables were transformed 
into dichotomous variables. Based on previous stud-
ies we established an interval of 100 days as the optimal 
diagnostic interval, and 30 days for the optimal treatment 
interval [12–14]. Firstly, an empty model was adjusted 
considering only the random effect of hospital’s location 
based on the variability of the two outcomes investigated. 
Univariate models where then adjusted for each potential 
predictor. The final model was fitted through a backward 
selection procedure based on the Wald tests results. Both 
the empty model and the final multilevel models were 
estimated by maximum likelihood using the adaptive 
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Fig. 1 Time intervals considered in our study
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Gaussian quadrature approximation (with seven quadra-
ture points) [15].
The effect measure was the odds ratio (OR) with 95% 
confidence interval, and was considered statistically sig-
nificant if p < 0.05. We calculated the intra-cluster corre-
lation coefficient (ICC) and the median odds ratio (MOR) 
to estimate the random inter-hospital variability. A lower 
ICC indicates a lower probability of patients sharing sim-
ilar hospital experiences. The MOR is the increased risk 
of moving a patient to a hospital with longer diagnostic 
and therapeutic intervals [16]. The statistical software 
used was SPSS, v20.0 (SPSS INC., Chicago, IL, United 
States of America) and Stata, v12.1 (College Station, TX: 
StataCorp LP).
Results
Of the 347 patients recruited, 314 patients participated in 
the study and 33 were excluded for not meeting the inclu-
sion criteria. Mean age was 70.3  years (SD: 11.2), 267 
(85.0%) were male, 194 (61.9%) had at least completed 
primary studies, and 216 (68.8%) were retired (Table 1). 
The mean BMI was 27.2 (SD: 4.8) and 180 (57.3%) 
patients were full active according to the ECOG WHO 
performance status. The Charlson co-morbidity index 
was between one and three for 284 patients (90.5%). 
First consultation for bladder-related symptoms was 
performed in primary care settings for 151 participants 
(48.1%), and in hospital settings for the remaining 138 
patients (43.9%). In 9.8% of the patients, the disease was 
diagnosed during a routine visit; in these cases, patients 
did not report symptoms, or only a certain degree of 
discomfort caused by the bladder cancer. From the total 
group, 85.0% were symptomatic; being hematuria the 
most frequent symptom (73.9%). The time from the first 
symptoms to first consultation was between 1 month and 
1 year for 60.5% of the participants. The most common 
pathologic malignant diagnosis was urothelial cell carci-
noma (90.1%). Other pathologic diagnoses were adeno-
carcinoma (8.6%), and squamous cell carcinoma (0.6%). 
The most frequent primary tumor clinical stage was T1 
(45.9%).
A bladder ultrasound was reported in 79.0% of the 
patients and a cystoscopy in 52.2% (Additional file  3). 
The median diagnostic time interval was 104.0 days (IQR: 
112.0) (Table 1). A statistically significant variability was 
found among hospitals for this interval (MOR: 1.47, 95% 
CI: 1.14–3.06) (Table  2). Patients who went to primary 
care setting presented an OR of 1.64 (95% CI 1.03–2.63, 
p  =  0.038) of having a diagnostic interval longer than 
100  days compared to patients who were first attended 
at the hospital. Furthermore, patients who experienced 
first symptoms longer than 1 month presented an OR of 
2.38 (95% CI 1.25–4.51, p = 0.008) of having a diagnostic 
interval longer than 100 days compared to patients who 
experienced their symptoms in less than 1 month. There 
were no significant differences in terms of gender, age, 
BMI, educational level, ECOG WHO score, or primary 
tumor stages (Table 2; Additional file 4). The multivariate 
analysis did not show statistically significant variability 
among hospitals for this time interval.
The median therapeutic interval was 0.0 days (IQR: 0.0) 
(Table  1). There was a statistically significant variabil-
ity among hospitals for this interval (MOR: 2.81, 95% CI 
1.56–11.06, p < 0.001). Patients with a BMI ≥ 25 showed 
a significant lower odd of having a therapeutic inter-
val longer than 30  days (OR =  0.39; 95% CI 0.16–0.94, 
p = 0.037). Patients in a tumor stage from T2a–T4b pre-
sented an OR of 4.39 (95% CI 1.72–11.21, p = 0.002) of 
having a therapeutic interval longer than 30  days com-
pared to patients with inferior clinical stages. No signifi-
cant differences were found within the other outcomes. 
The multivariate analysis showed statistically significant 
variability among hospitals in the therapeutic inter-
val and the only factor that significantly influenced this 
interval was the tumor stage (Table 2).
Discussion
Our multicenter study in Spain included 314 patients 
mostly diagnosed with bladder urothelial cell carcinoma. 
The population characteristics were similar to those 
described in previously published studies [2, 17–21]. The 
majority of bladder cancers started with symptoms, being 
hematuria the most frequent. The percentage (42.3%) of 
localized tumors was similar to another study conducted 
in Spain [2], but considerably higher than other previous 
studies [17, 21].
Most patients in our study population had an early 
stage of bladder cancer and the diagnosis interval was 
relatively long, with a median of 104.0 days. Patients who 
experienced first symptoms for no longer than 1 month 
before the first consultation and those who went to a 
hospital for their first consultation had a significantly 
narrower diagnostic interval; this was expected as the 
hospital has the possibility of performing TUR (Tran-
sUrethral Resection) and biopsy (diagnosis of certainty 
and treatment), and in primary care only basic imaging 
tests. There was not significant variability among hospi-
tals in relation to this time interval. The delay in diagnos-
tic interval is concordant with other studies [22, 23], and 
consequently some European initiatives have emerged 
to narrow this interval [24–26]. These initiatives suggest 
that expediting the initial ultrasonography/cystoscopy 
in all patients could improve the time of diagnosis and 
treatment for bladder cancer. The European Association 
of Urology guideline recommends ultrasound as one of 
the initial staging techniques for patients with hematuria, 
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and cystoscopy only for patients experiencing symptoms 
suggestive of bladder cancer [27].
Previous Spanish studies assessed the diagnostic and 
therapeutic time intervals in cancer patients, however 
they were mainly performed in a single hospital and they 
all included other types of cancer [28, 30], except for 
one conducted more than 20 years ago [29]. One Span-
ish multicenter study reported a mean treatment interval 
longer than ours (73.2  days) due to a different defini-
tion of this variable [13]. They measured the time from 
the first performed diagnostic tests and not from the 
date of histological confirmation of bladder cancer until 
treatment.
In addition, our results reveal that among centers there 
is a significant variability in terms of treatment intervals. 
Diverse population characteristics, health care organi-
zations (e.g. health care pathways connecting primary 
and specialized care) and clinical policies across the dif-
ferent Spanish regions may explain, at least in part, this 
observed heterogeneity.
Table 1 Characteristics of bladder cancer patients
Variables N = 314, n 
(%)/x ± SD
Mean age ± SD (years) 70.3 ± 11.2
 Missing (%) 1 (0.3)
Mean BMI ± SD (Kg/m2) 27.2 ± 4.8
 Missing 8 (2.5)
Sex
 Male 267 (85.0)
 Female 47 (15.0)
 Missing 0 (0.0)
Working status
 Active 48 (15.3)
 Sick leave 16 (5.1)
 Retired 216 (68.8)
 Unemployed 11 (3.5)
 Other 21 (6.7)
 Missing 2 (0.6)
Education
 No education 40 (12.8)
 Incomplete primary education 73 (23.2)
 Primary education 52 (16.6)
 Graduate school 66 (21.0)
 Upper secondary studies 36 (11.5)
 University 40 (12.8)
 Missing 7 (2.2)
ECOG WHO score
 Fully active 180 (57.3)
 Restricted 106 (33.8)
 Unable to work/only self‑care activities/bedridden 26 (8.3)
 Missing 2 (0.6)
Setting first consultation
 Primary care 151 (48.1)
 Hospital 138 (43.9)
 Other 15 (4.8)
 Missing 10 (3.2)
Symptoms
 No symptoms or discomfort 47 (15.0)
 One or more symptoms 267 (85.0)
 Missing 0 (0.0)
Charlson index
 1–3 284 (90.5)
 4 9 (2.9)
 ≥ 5 21 (6.6)
Start of first symptoms including patients with discomfort before first 
consult
 Up to 1 month 52 (16.6)
 Between 1 month and 1 year 190 (60.5)
 More than 1 year 53 (16.9)
 Missing 19 (6.0)
Primary tumour clinical stage (T)
 Tx 9 (2.9)
Table 1 continued
Variables N = 314, n 
(%)/x ± SD
 Ta 91 (29.0)
 Tis 8 (2.6)
 T1 144 (45.9)
 T2a–b 50 (15.9)
 T3a–b 7 (2.3)
 T4a–b 4 (1.3)
 Missing 1 (0.1)
Node stage (N)
 Nx 88 (28.0)
 No 213 (67.9)
 N1 6 (2.0)
 N2 6 (2.0)
 N3 1 (0.1)
 Missing 0 (0.0)
Metastasis stage (M) (%)
 Mx 0 (0.0)
 M0 303 (96.5)
 M1 11 (3.5)
 Missing 0 (0.0)
Median interval time between first consultation and 
diagnosis in days ± IQR (range)
104.0 ± 112.0 
(from 0 to 986)
 Missing 7 (2.3)
Median interval time between diagnosis and first 
treatment ± IQR (range)
0.0 ± 0.0 (from 0 
to 366)
 Missing 0 (0.0)
Median interval time between first consultation and 
first treatment ± IQR (range)
109.0 ± 120.7 
(from 0 to 986)
 Missing 6 (1.9)
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Some patients’ and tumor features were also associated 
with the length of time between diagnosis and treatment; 
e.g. among patients with a higher primary tumor clinical 
stage. This finding may be explained because this group 
of patients is generally treated with cystectomy and 
chemotherapy and require a more complex process than 
a TUR approach.
Limitations
This study may be prone to some limitations. Information 
bias is a potential issue as the study is based exclusively 
on information obtained from hospital clinical records. 
As a result, some outpatient factors, such as those related 
to consultations in primary care settings, may not have 
been properly forethought.
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